The company has posted net profit of Rs.19.8 crores for the period ended December 31, 2020 as against net loss of Rs. 569.7 crores for the period ended December 31, 2019.
The company has reported total income of Rs.14759 crores during the 9 months period ended December 31, 2020.
Post approval under the PLI scheme, Aurobindo will become a very large player in anti-biotic space.
With a mix of vaccines targeting different stages of COVID-19, the company is eyeing huge market potential
This vaccination programme is based on the principles of priority groups to be vaccinated and health care workers both in the government and private sectors including ICDS workers will receive the vaccine during this phase.
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
